Prolactin inhibits oocyte release after gonadotropin stimulation in the rat: Putative mechanism involving ovarian production of beta-endorphin and prostaglandin

Slides:

Advertisements

Similar presentations

The effectiveness of gonadotropin-releasing hormone antagonist in poor ovarian responders undergoing in vitro fertilization: a systematic review and meta-analysis

Advertisements

Krinos M. Trokoudes, M. D. , Constantinos Pavlides, M. Sc

Is the type of gonadotropin-releasing hormone suppression protocol for ovarian hyperstimulation associated with ectopic pregnancy in fresh autologous.

Gonadotropin-releasing hormone agonist trigger in oocyte donors co-treated with a gonadotropin-releasing hormone antagonist: a dose-finding study Thi.

Luteal-phase ovarian stimulation is feasible for producing competent oocytes in women undergoing in vitro fertilization/intracytoplasmic sperm injection.

Gonadotropin-releasing hormone agonist trigger increases the number of oocytes and embryos available for cryopreservation in cancer patients undergoing.

Fernando Zegers-Hochschild, M.D. Fertility and Sterility

Triggering with human chorionic gonadotropin or a gonadotropin-releasing hormone agonist in gonadotropin-releasing hormone antagonist-treated oocyte donor.

1,500 IU human chorionic gonadotropin administered at oocyte retrieval rescues the luteal phase when gonadotropin-releasing hormone agonist is used for.

Michael M. Alper, M.D. Fertility and Sterility

Administration of a gonadotropin-releasing hormone antagonist during the 3 days before the initiation of the in vitro fertilization/intracytoplasmic sperm.

Zhi-Yong Yang, M.D., Ri-Cheng Chian, Ph.D. Fertility and Sterility

Ovarian pregnancy after in vitro fertilization

Growth rates of ovarian follicles during natural menstrual cycles, oral contraception cycles, and ovarian stimulation cycles Angela R. Baerwald, Ph.D.,

Cem Atabekoglu, M. D. , Murat Sonmezer, M. D. , Sinan Özkavukcu, M. D

Isabel Cerveira, M. D. , Cristina Costa, M. D. , Fernando Santos, M. D

Evaluation of the immature human oocytes from unstimulated cycles in polycystic ovary syndrome patients using a novel scoring system Shan Liu, M.D.,

Cutoff value of human chorionic gonadotropin in relation to the number of methotrexate cycles in the successful treatment of ectopic pregnancy Ewa Nowak-Markwitz,

Effect of the oxytocin antagonist antocin and agonist decomoton on baboon luteal cell production and release of progesterone M. Yusoff Dawood, M.D.,

Medical treatment of ectopic pregnancy: a committee opinion

Follicle-stimulating hormone administered at the time of human chorionic gonadotropin trigger improves oocyte developmental competence in in vitro fertilization.

The relative contribution of assisted reproductive technologies and ovulation induction to multiple births in the United States 5 years after the Society.

Live birth of twins derived from zona-free oocytes

Inhibition of cyclooxygenase-2 (COX-2) by meloxicam decreases the incidence of ovarian hyperstimulation syndrome in a rat model Ramiro Quintana, M.D.,

Grant D.E. McWilliams, D.O., John L. Frattarelli, M.D.

Improvement of in vitro culture of mouse cumulus–oocyte complexes using PDE3- inhibitor followed by meiosis induction with epiregulin Sergio Romero, M.Sc.,

A comparison of blood spot vs

The role of steroid hormone supplementation in non–assisted reproductive technology treatments for unexplained infertility Alexander M. Quaas, M.D.,

María Guillermina Bilbao, Ph. D. , María Paula Di Yorio, Ph. D

Selection of patients for natural cycle in vitro fertilization combined with in vitro maturation of immature oocytes Jin-Ho Lim, M.D., Seong-Ho Yang,

Improved monofollicular ovulation in anovulatory or oligo-ovulatory women after a low- dose step-up protocol with weekly increments of 25 international.

Oocyte cryopreservation

Establishing a human chorionic gonadotropin cutoff to guide methotrexate treatment of ectopic pregnancy: a systematic review Seema Menon, M.D., John.

Robert F. Casper, M.D. Fertility and Sterility

Ultrashort flare gonadotropin-releasing hormone (GnRH) agonist/GnRH antagonist protocol: a valuable tool in the armamentarium of ovulation induction for.

The effectiveness of gonadotropin-releasing hormone antagonist in poor ovarian responders undergoing in vitro fertilization: a systematic review and meta-analysis

Management of tubal ectopic pregnancy: methotrexate and salpingostomy are preferred to preserve fertility Stephanie Beall, M.D., Ph.D., Alan H. DeCherney,

Treatment of Ovarian Hyperstimulation Syndrome Utilizing a Dopamine Agonist and Gonadotropin Releasing Hormone antagonist N. Rollene, M. Amols, S. Hudson,

Akanksha Mehta, M.D., Darius A. Paduch, M.D., Ph.D.

Granulosa–lutein cell growth differentiation factor-9 (GDF-9) messenger RNA and protein expression in in vitro fertilization (IVF) cycles: relation to.

Retrieval of immature oocytes after chemotherapy for Hodgkin's disease and prolonged ovarian down-regulation with gonadotropin-releasing hormone agonist

Changes in cytokine levels of patients with ovarian endometriosis after treatment with gonadotropin-releasing hormone analogue, ultrasound-guided drainage,

Birth outcomes after spontaneous or assisted conception among infertile Australian women aged 28 to 36 years: a prospective, population-based study Danielle.

Prospective cohort study of three- versus two-dimensional ultrasound for prediction of oocyte maturity Doron Shmorgun, M.D., Edward Hughes, M.D., Patrick.

David E. Reichman, M. D. , Stacey A. Missmer, Sc. D. , Katharine F

Ri-Cheng Chian, Ph.D., Peter S. Uzelac, M.D., Geeta Nargund, M.D.

Effectiveness of highly purified human menopausal gonadotropin vs

Viability and function of the cryopreserved whole rat ovary: comparison between slow- freezing and vitrification Milan Milenkovic, M.D., Ph.D., César.

Effect of leptin on prolactin and insulin-like growth factor-I secretion by cultured rat endometrial stromal cells Kamani H. Tennekoon, Ph.D., Thampoe.

Pregnancy outcome in infertile patients with polycystic ovary syndrome who were treated with metformin Samuel S. Thatcher, M.D., Ph.D., Elizabeth M.

Human granulosa-lutein cell in vitro production of progesterone, inhibin A, inhibin B, and activin A are dependent on follicular size and not the presence.

L. Scott, J. Bernsten, K. DeLegge, J. Hill, N. Ramsing

Reducing the dose of human chorionic gonadotropin in high responders does not affect the outcomes of in vitro fertilization David W. Schmidt, M.D.,,

Upregulation of mRNA expression of vascular endothelial growth factor and its receptors by exogenous human chorionic gonadotropin in cultured oviduct.

Follicular phase serum levels of luteinizing hormone do not influence delivery rates in in vitro fertilization cycles down-regulated with a gonadotropin-releasing.

David H. Barad, M.D., M.S., Norbert Gleicher, M.D.

A new era in ovulation induction

Comparing anti-Müllerian hormone (AMH) and follicle-stimulating hormone (FSH) as predictors of ovarian function David H. Barad, M.D., M.S., Andrea Weghofer,

In vitro sildenafil citrate use as a sperm motility stimulant

Transforming growth factor-β1 and its receptor soluble endoglin are altered in polycystic ovary syndrome during controlled ovarian stimulation Reshef.

Krinos M. Trokoudes, M. D. , Constantinos Pavlides, M. Sc

Progesterone level and progesterone/estradiol ratio on the day of hCG administration: detrimental cutoff levels and new treatment strategy Eman A. Elgindy,

Claude Régis Lacoste, M. D. , Alix Clemenson, M. D. , Suzanne Lima, M

Intrafollicular antimüllerian hormone levels predict follicle responsiveness to follicle- stimulating hormone (FSH) in normoandrogenic ovulatory women.

A novel “delayed start” protocol with gonadotropin-releasing hormone antagonist improves outcomes in poor responders Hakan Cakmak, M.D., Nam D. Tran,

Ovarian hyperstimulation syndrome prevention by gonadotropin-releasing hormone agonist triggering of final oocyte maturation in a gonadotropin-releasing.

In vitro viability and secretory capacity of human luteinized granulosa cells after gonadotropin-releasing hormone agonist trigger of oocyte maturation

Effect of oocyte quality on blastocyst development after in vitro fertilization (IVF) and intracytoplasmic sperm injection (ICSI) in a sheep model Maria.

Logarithmic curves depicting initial level and rise of serum beta human chorionic gonadotropin and live delivery outcomes with in vitro fertilization:

Oocyte retrieval timing based on spontaneous luteinizing hormone surge during natural cycle in vitro fertilization treatment Daniel Bodri, M.D., M.Sc.,

Presentation transcript:

Prolactin inhibits oocyte release after gonadotropin stimulation in the rat: Putative mechanism involving ovarian production of beta-endorphin and prostaglandin Fernanda Polisseni, M.D., Alicia G. Faletti, Ph.D., Virginia M. Pereira, M.Sc., Adelina M. Reis, Ph.D., Aroldo F. Camargos, M.D., Ph.D., Fernando M. Reis, M.D., Ph.D. Fertility and Sterility Volume 83, Issue 4, Pages 1119-1124 (April 2005) DOI: 10.1016/j.fertnstert.2004.07.981 Copyright © 2005 American Society for Reproductive Medicine Terms and Conditions

FIGURE 1 Effects of prolactin (PRL) (100 or 200 μg) and PRL + naloxone (200 μg each) on the number of oocytes recovered in the oviducts of superovulated rats. *P<.05; **P<.01 vs. control (Student-Newman-Keuls test). Other comparisons between treatments were not statistically significant. Fertility and Sterility 2005 83, 1119-1124DOI: (10.1016/j.fertnstert.2004.07.981) Copyright © 2005 American Society for Reproductive Medicine Terms and Conditions

FIGURE 2 Representative photomicrographs of preovulatory follicles from rats treated with (a) saline vehicle or (b) 200 μg prolactin (PRL) 4 hours after hCG injection for ovulation induction. Magnification was ×200. Fertility and Sterility 2005 83, 1119-1124DOI: (10.1016/j.fertnstert.2004.07.981) Copyright © 2005 American Society for Reproductive Medicine Terms and Conditions

FIGURE 3 Effects of prolactin (PRL) (100 or 200 ng/mL) on the isolated rat ovary in vitro. (A), Beta-endorphin release; (B), prostaglandin E2 release; (C), NO synthase activity (expressed as picomoles of NO per gram w.w. per minute); and (D), NO2−/NO3− release (expressed by the NO2− concentration after NO3− reduction). *P<.05 vs. control (Student-Newman-Keuls test). Fertility and Sterility 2005 83, 1119-1124DOI: (10.1016/j.fertnstert.2004.07.981) Copyright © 2005 American Society for Reproductive Medicine Terms and Conditions